CCL19 como biomarcador de respuesta a Anti PDL 1 en melanoma y asociado a Vitiligo.

Journal Scan / Research · January 05, 2020

Immune Checkpoint Inhibitor–Induced Vitiligo in Advanced Melanoma Could Be Related to Increased Levels of CCL19

The British Journal of Dermatology

TAKE-HOME MESSAGE

• This study included 57 patients treated with nivolumab or pembrolizumab for advanced melanoma. A significantly higher change in CCL19 at day 42 of treatment compared with baseline values was seen in patients who developed vitiligo (P<.001) and in those who showed an objective response to therapy at that time point (P=.01).

• Change in CCL19 may serve as a biomarker to predict both the development of vitiligo and the efficacy of therapy in patients treated with anti–PD-1 immunotherapy for advanced melanoma.

– Caroline K. Crabtree, MD

Abstract 

Immune checkpoint inhibitors (ICIs) are in wide use for the treatment of various cancers. Although anti‐programmed cell death (PD)1 antibody‐based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of immune‐related adverse events (irAEs) is an important consideration. In contrast to these severe AEs, vitiligo is reported to correlate with improved prognosis among patients with advanced melanoma treated with ICI therapy.3 Indeed, vitiligo correlated with statistically significant differences in overall survival among patients with metastatic melanoma.

The British Journal of Dermatology

Immune Checkpoint Inhibitor-Induced Vitiligo in Advanced Melanoma Could Be Related to Increased Levels of CCL19

Br J Dermatol 2019 Nov 20;[EPub Ahead of Print], T Fujimura, K Tanita, Y Sato, C Lyu, Y Kambayashi, Y Fujisawa, H Uchi, Y Yamamoto, A Otsuka, K Yoshino, S Matsushita, T Funakoshi, S Fukushima, H Hata, A Hashimoto, S Aiba 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.